A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data.
Andreas Schneeweiss
Consultant or Advisory Role - Lilly; Sanofi
Honoraria - Lilly; Sanofi
Research Funding - Lilly
Amparo Ruiz
No relevant relationships to disclose
Alexey Manikhas
No relevant relationships to disclose
Alberto Bottini
No relevant relationships to disclose
Pedro Sanchez Rovira
No relevant relationships to disclose
Kambiz Mansouri
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Gbenga Kazeem
Employment or Leadership Position - Lilly
Thomas Bauknecht
Employment or Leadership Position - Lilly
Stock Ownership - Lilly